CalciMedica, Inc.
CALCCalciMedica, Inc. in brief
CalciMedica, Inc. is a listed company in the Biotechnology industry, based in California, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,531st largest listed company in the world and the 4,261st largest in the USA on this site. It employs about 16 people and A. Rachel Leheny is its chief executive. Its shares trade under the symbol CALC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CalciMedica, Inc.
Graybug Vision is a Clinical Stage Biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. It is having 37 employees as on 2020. The headquarters is in USA.
CalciMedica, Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- ✎Renamed GRAYBUG, Inc.Formerly Graybug Llc.
- 2016
- ✎Renamed Graybug Vision, Inc.Formerly GRAYBUG, Inc..
- 2020
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as Graybug Vision, Inc.Final prospectus filed with the SEC on 25 September 2020; shares registered for exchange trading on 21 September 2020.
- 2023
- ✎Renamed CalciMedica, Inc. /DE/Formerly Graybug Vision, Inc..
- ✎Renamed CalciMedica, Inc.Formerly CalciMedica, Inc. /DE/.
Events of CalciMedica, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,595 (Jan 2021) · #5,095 (Jan 2022) · #5,529 (Dec 2022) · #4,282 (Oct 2026) · #4,264 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -175.7%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 148.9%
- Profit per employee
- $-1.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-23M | $-30M | — |
| Dec 2024 | — | — | $-24M | $-14M | — |
| Dec 2023 | — | — | $-38M | $-34M | — |
| Dec 2022 | — | — | $-14M | $-8M | — |
| Dec 2021 | — | — | $-36M | $-36M | — |
| Dec 2020 | — | — | $-30M | $-28M | — |
| Dec 2019 | — | — | $-38M | $-37M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-21M | $0M | $-21M | $-1.97 | — |
| Dec 2024 | $-21M | $0M | $-21M | $-1.22 | — |
| Dec 2023 | $-26M | $0M | $-26M | $-7.66 | — |
| Dec 2022 | $-12M | $0M | $-12M | $-111.16 | — |
| Dec 2021 | $-32M | $0M | $-32M | $-1.69 | — |
| Dec 2020 | $-32M | $1M | $-33M | $-5.25 | — |
| Dec 2019 | $-31M | $1M | $-32M | $-33.41 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 16, 20268-KCurrent reportDirectors or officers changed
- Sep 30, 20268-KCurrent reportOther events
- Sep 16, 20268-KCurrent reportOther events
- Sep 2, 20268-KCurrent reportOther events
- Aug 27, 20268-KCurrent reportBylaws amended
- Aug 20, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 23, 2026DEF 14AProxy statement
- Jul 7, 20268-KCurrent reportDirectors or officers changed
Official filings of CalciMedica, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-23 M
- Net income
- $-30 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $14 M
- Total liabilities
- $20 M
- Total equity
- $-7 M
As of December-2025
Top 17 institutional investors in CalciMedica, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Woodline Partners LP | 497,945 | New | 7.22% | $1 M | Nov 16, 2026 |
| 2 | Armistice Capital, LLC | 388,641 | New | 5.64% | $1 M | Nov 16, 2026 |
| 3 | Stonepine Capital Management, LLC | 278,680 | New | 4.04% | $0 M | Nov 13, 2026 |
| 4 | Stempoint Capital LP | 248,972 | New | 3.61% | $0 M | Nov 16, 2026 |
| 5 | Heights Capital Management, Inc | 163,728 | New | 2.37% | $0 M | Nov 16, 2026 |
| 6 | Renaissance Technologies LLC | 47,980 | New | 0.70% | $0 M | Nov 12, 2026 |
| 7 | Geode Capital Management, LLC | 25,437 | New | 0.37% | $0 M | Nov 6, 2026 |
| 8 | Cambridge Investment Research Advisors, Inc. | 16,450 | New | 0.24% | $0 M | Nov 2, 2026 |
| 9 | Jane Street Group, LLC | 15,000 | New | 0.22% | $0 M | Nov 12, 2026 |
| 10 | Rockefeller Capital Management L.P. | 4,000 | New | 0.06% | $0 M | Nov 13, 2026 |
| 11 | Tower Research Capital LLC (TRC) | 2,535 | New | 0.04% | $0 M | Nov 16, 2026 |
| 12 | Jpmorgan Chase & Co | 2,444 | New | 0.04% | $0 M | Nov 12, 2026 |
| 13 | Brown Brothers Harriman & Co | 60 | New | 0.00% | $0 M | Nov 13, 2026 |
| 14 | Osaic Holdings, Inc. | 21 | New | 0.00% | $0 M | Nov 12, 2026 |
| 15 | SBI Securities Co., Ltd. | 17 | New | 0.00% | $0 M | Oct 22, 2026 |
| 16 | Wells Fargo & Company/mn | 2 | New | 0.00% | $0 M | Nov 16, 2026 |
| 17 | UBS Group AG | 2 | New | 0.00% | $0 M | Nov 10, 2026 |
Insider trading at CalciMedica, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Robert N. WilsonDirector | Grant or award | +1.18 M | $0.800 | $946 K | 1.60 M | Form 4 |
| filed | Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% owner | Grant or award | +186,729 | $0.800 | $149 K | 366,435 | Form 4 |
| filed | Sudarshan HebbarChief Medical Officer | Grant or award | +124,486 | $0.800 | $100 K | 186,025 | Form 4 |
| filed | Fred A. MiddletonDirector, 10% owner | Buyindirect | +248,972 | $0.800 | $199 K | 1.06 M | Form 4 |
| filed | A. Rachel LehenyCHIEF EXECUTIVE OFFICER, Director, 10% owner | Grant or award | +186,729 | $0.800 | $149 K | 317,655 | Form 4 |
| filed | Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% owner | Buyindirect | +2,500 | $3.070 | $8 K | 84,150 | Form 4 |
| filed | Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% owner | Buyindirect | +3,400 | $2.680 | $9 K | 81,650 | Form 4 |
| filed | Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% owner | Buyindirect | +5,000 | $3.120 | $16 K | 78,250 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CalciMedica, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1 split ; 1-for-9.01 reverse split
Trading halts
- 2026-08-28 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-01-28 15:57 UTC, code LUDP, resumed 16:02 UTC
- 2026-01-28 15:50 UTC, code LUDP, resumed 15:55 UTC
- 2026-01-28 15:44 UTC, code LUDP, resumed 15:49 UTC
- 2026-01-28 15:38 UTC, code LUDP, resumed 15:43 UTC
Fails to deliver
- : 1,372 shares at $1.75
- : 1,638 shares at $1.66
- : 138 shares at $1.15
- : 3,779 shares at $1.15
- : 658 shares at $1.21
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CalciMedica, Inc. scorecard#
Passes 1 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-175.7%Free cash flow is -175.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.97 vs -1.22Diluted EPS -1.97 in fiscal 2025 against -1.22 the year before (report's currency).
- ✗Net income higher than five years earlier-$30 M-$30 M in fiscal 2025 against -$28 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$30 MNet income -$30 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.58 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year33.5%Diluted shares up 33.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
CalciMedica, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | 15+5.2%— | 14−8.7%— | 16+89.9%— | 8.4r14−55.8%— | 19−9.8%— | 21−31.5%— | 31—— | |
| General and administrative | 7.9−18.9%— | 9.7−56.2%— | 22+280%— | 5.8r19−65.7%— | 17+92.2%— | 8.9+28.1%— | 6.9—— | |
| Operating expenses | 23−4.5%— | 24−36.4%— | 38+168%— | 14r36−60.5%— | 36+20.5%— | 30−20.5%— | 38—— | |
| Operating income | −23—— | −24—— | −38—— | −14r−36—— | −36—— | −30—— | −38—— | |
| Interest and finance income | — | — | — | 0.6+356%— | 0.1−11.9%— | 0.1−63.6%— | 0.4—— | |
| Interest expense and finance costs | 1.4—— | 0—— | — | — | — | — | — | |
| Non-interest income | 0.7−29.7%— | 1.0—— | — | — | — | — | — | |
| Other non-operating income (expense) | −6.4−161%— | 11+183%— | 3.7−41.6%— | 6.4—— | — | — | — | |
| Income before tax | −30—— | −14—— | — | — | — | — | — | |
| Income tax | 0—— | 0−100%— | 0.00.0%— | 0.0—— | — | — | — | |
| Net income including minority interests | −30—— | −14—— | −34—— | −7.8r−36—— | −36—— | −28—— | −37—— | |
| Net income attributable to shareholders | −30—— | −14—— | −34—— | −7.8r−36—— | −36—— | −28—— | −37—— | |
| Earnings per share, basic | -1.97—— | -1.22—— | -7.66—— | -111.16r-1.66—— | -1.69—— | -5.25—— | -33.41—— | |
| Earnings per share, diluted | -1.97—— | -1.22—— | -7.66—— | -111.16r-1.66—— | -1.69—— | -5.25—— | -33.41—— | |
| Shares, weighted average (basic) | 15+33.5%— | 11+151%— | 4.5+5355%— | 0.1r21−99.6%— | 21—— | — | — | |
| Shares, weighted average (diluted) | 15+33.5%— | 11+151%— | 4.5+5355%— | 0.1r21−99.6%— | 21+220%— | 6.6+401%— | 1.3—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 12+45.2%84.8% | 7.9+43.5%40.1% | 5.5+317%45.4% | 1.3r17−90.1%39.6% | 13−60.0%19.3% | 33+111%32.8% | 16—39.0% | |
| Short-term investments | 1.5−86.1%11.0% | 11+88.1%54.2% | 5.7—46.8% | 0r22−100%0.0% | 50−18.4%72.8% | 62+207%60.5% | 20—49.4% | |
| Other current assets | 0.3+4.4%1.9% | 0.2−16.2%1.3% | 0.3r0.4+16.5%2.4% | 0.3r0.5−81.2%7.6% | 1.4r1.4−7.5%2.0% | 1.5r4.2+364%1.4% | 0.3—0.8% | |
| Current assets | 14−31.2%99.6% | 20+69.5%99.3% | 12+571%95.2% | 1.7r40−97.4%51.7% | 67−32.4%97.1% | 99+174%97.5% | 36—89.2% | |
| Property, plant and equipment | 0.1−58.0%0.4% | 0.1−28.7%0.6% | 0.2+13.6%1.4% | 0.1−92.6%4.4% | 2.0+1.8%2.9% | 1.9−1.5%1.9% | 2.0—4.9% | |
| Right-of-use (leased) assets | — | — | 0−100%0.0% | 0.0—1.4% | — | — | — | |
| Total assets | 14−31.3%100% | 20+62.4%100% | 12+264%100% | 3.3r40−95.2%100% | 69−32.1%100% | 102+150%100% | 41—100% | |
| Accounts payable | 1.2−41.9%8.5% | 2.0+40.8%10.1% | 1.4−50.5%11.6% | 2.9r1.7+444%85.6% | 0.5−79.0%0.8% | 2.5−45.8%2.5% | 4.6—11.4% | |
| Current liabilities | 3.8+2.7%27.8% | 3.7−8.5%18.6% | 4.0−15.7%33.1% | 4.8r3.7+17.8%143% | 4.1−42.0%5.9% | 7.0−42.9%6.9% | 12—30.1% | |
| Total liabilities | 20+276%149% | 5.4+33.7%27.2% | 4.0−68.0%33.1% | 13r3.7+210%376% | 4.1−42.0%5.9% | 7.0−42.8%6.9% | 12—30.1% | |
| Retained earnings | −189—−1393% | −160—−807% | −146—−1199% | −112r−205—−3336% | −169—−245% | −133—−131% | −106—−260% | |
| Shareholders' equity | −6.6−146%−48.9% | 14+76.7%72.8% | 8.2—66.9% | −71r36—−2129% | −64r65−168%−92.6% | 95—93.1% | −103—−253% | |
| Total liabilities and equity | 14−31.3%100% | 20+62.4%100% | 12+264%100% | 3.3r40−95.2%100% | 69−32.1%100% | 102+150%100% | 41—100% | |
| Shares outstanding | 3.1r15−77.1%— | 13+134%— | 5.8+6737%— | 0.1r22−99.6%— | 21+1.8%— | 21+1430%— | 1.4—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | — | — | 0.1+11.5%— | 0.1—— | — | — | — | |
| Share-based compensation | 3.0+28.4%— | 2.3−80.8%— | 12+566%— | 1.8r6.7−66.4%— | 5.4+201%— | 1.8+142%— | 0.7—— | |
| Cash from operating activities | −21—— | −21—— | −26—— | −12r−23—— | −32—— | −32—— | −31—— | |
| Capital expenditure | −0.0—— | −0.0—— | −0.1—— | −0.0r−0.3—— | −0.5—— | −1.0—— | −0.6—— | |
| Cash from investing activities | 9.6—— | −4.4−150%— | 8.9—— | −0.0r27−100%— | 11—— | −43—— | −21—— | |
| Shares issued | 0.0−100.0%— | 28+170%— | 10—— | — | — | 96—— | — | |
| Cash from financing activities | 15−45.6%— | 28+33.8%— | 21+147%— | 8.5r−0.1+1120%— | 0.7−99.2%— | 92+68.0%— | 55—— | |
| Change in cash | 3.6+49.1%— | 2.4−40.7%— | 4.1—— | −3.3r3.9—— | −20−214%— | 18+478%— | 3.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 11−31.0%— | 2.3−39.8%— | 2.1−48.1%— | 3.5−17.5%— | 3.1*−18.9%— | 3.9+8.6%— | 4.1−2.5%— | 4.2+43.5%— | 3.8*+37.7%— | 3.5—— | 4.2—— | 2.9—— | 2.8*—— | |
| General and administrative | 7.7−13.5%— | 2.4+37.6%— | 1.9−25.7%— | 2.1−6.5%— | 1.3*−45.4%— | 1.8−19.3%— | 2.6+8.3%— | 2.3−19.5%— | 2.3*+52.3%— | 2.2—— | 2.4—— | 2.8—— | 1.5*—— | |
| Operating expenses | 19−24.7%— | 4.8−15.4%— | 4.0−39.4%— | 5.6−13.6%— | 4.4*−29.0%— | 5.6−2.1%— | 6.6+1.4%— | 6.5+12.7%— | 6.2*+42.9%— | 5.7—— | 6.5—— | 5.8—— | 4.3*—— | |
| Operating income | −19—— | −4.8—— | −4.0—— | −5.6—— | −4.4*—— | −5.6—— | −6.6—— | −6.5—— | −6.2*—— | −5.7—— | −6.5—— | −5.8—— | −4.3*—— | |
| Interest expense and finance costs | 1.3+20.9%— | 0.4+9.5%— | 0.3+0.3%— | 0.3−28.6%— | 0.3*—— | 0.3—— | 0.3—— | 0.4—— | 0*—— | 0—— | 0—— | 0—— | — | |
| Non-interest income | 0.4−42.7%— | 0.1−4.3%— | 0.1−75.5%— | 0.1−47.5%— | 0.2*−29.4%— | 0.1−35.8%— | 0.2−20.0%— | 0.2−34.2%— | 0.2*—— | 0.2—— | 0.3—— | 0.3—— | — | |
| Other non-operating income (expense) | 3.6+97.5%— | 3.1—— | −3.6−647%— | 11+628%— | −6.4*−433%— | −2.2−1953%— | 0.7−74.2%— | 1.5−75.3%— | 1.9*+1006%— | 0.1—— | 2.6—— | 5.9—— | 0.2*—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*−100%— | 0—— | 0—— | 0—— | 0.0*—— | |
| Net income including minority interests | −15—— | −1.7*—— | −7.7*—— | 5.0—— | −11*—— | −7.8*—— | −6.0*—— | −5.0−3978%— | −4.3*—— | −5.6*—— | −4.0*—— | 0.1—— | −4.1*—— | |
| Net income attributable to shareholders | −15—— | −1.7—— | −7.7—— | 5.0—— | −11*—— | −7.8—— | −6.0—— | −5.0−3978%— | −4.3*—— | −5.6—— | −4.0—— | 0.1—— | −4.1*—— | |
| Earnings per share, basic | — | -0.24—— | -0.45—— | 0.31—— | — | -2.59r-0.52—— | -0.40—— | -0.36−3700%— | — | -0.50—— | -0.36—— | 0.01—— | — | |
| Earnings per share, diluted | — | -0.24—— | -0.45—— | 0.30—— | — | -2.59r-0.52—— | -0.40—— | -0.36−3700%— | — | -0.50—— | -0.36—— | 0.01—— | — | |
| Shares, weighted average (basic) | 6.9+129%— | 6.9+129%— | 17+14.0%— | 16+12.0%— | — | 3.0r15−72.9%— | 15+34.7%— | 14+44.8%— | — | 11—— | 11—— | 9.8—— | — | |
| Shares, weighted average (diluted) | 6.9+129%— | 6.9+129%— | 17+14.0%— | 16+15.6%— | — | 3.0r15−72.9%— | 15+34.7%— | 14+40.5%— | — | 11—— | 11—— | 10—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.6—32.0% | 4.6−16.4%32.0% | 19+215%95.5% | 8.2−35.0%94.8% | 12+45.2%84.8% | 5.5−40.2%36.7% | 5.9+17.0%31.0% | 13+85.9%49.5% | 7.9+43.5%40.1% | 9.2—56.4% | 5.1—24.0% | 6.8—24.9% | 5.5—45.4% | |
| Short-term investments | 9.2—64.3% | 9.2+6.7%64.3% | 0−100%0.0% | 0−100%0.0% | 1.5−86.1%11.0% | 8.6+58.0%57.8% | 12−14.5%63.1% | 12−36.3%47.6% | 11+88.1%54.2% | 5.5—33.6% | 14—66.9% | 19—69.9% | 5.7—46.8% | |
| Other current assets | 0.4—3.0% | 0.4−19.9%3.0% | 0.6−12.2%2.9% | 0.1−38.1%1.4% | 0.3+4.4%1.9% | 0.5−50.2%3.6% | 0.7−49.8%3.4% | 0.2−78.0%0.8% | 0.2−16.2%1.3% | 1.1—6.7% | 1.3—6.2% | 0.9—3.3% | 0.3r0.4—2.4% | |
| Current assets | 14—99.5% | 14−4.3%99.5% | 19+2.6%99.8% | 8.6−66.1%99.4% | 14−31.2%99.6% | 15−5.3%99.6% | 19−7.2%99.4% | 25−5.2%99.5% | 20+69.5%99.3% | 16—96.8% | 20—97.1% | 27—98.0% | 12—95.2% | |
| Property, plant and equipment | 0.1—0.5% | 0.1+46.9%0.5% | 0.0−65.7%0.2% | 0.0−63.6%0.5% | 0.1−58.0%0.4% | 0.0−62.3%0.3% | 0.1−23.9%0.6% | 0.1−22.9%0.5% | 0.1−28.7%0.6% | 0.1—0.8% | 0.1—0.7% | 0.2—0.6% | 0.2—1.4% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 14—100% | 14−4.2%100% | 20+2.2%100% | 8.6−66.0%100% | 14−31.3%100% | 15−8.0%100% | 19−9.4%100% | 25−6.6%100% | 20+62.4%100% | 16—100% | 21—100% | 27—100% | 12—100% | |
| Accounts payable | 1.0—7.1% | 1.0−10.0%7.1% | 2.1+8.4%10.6% | 1.7−16.9%19.5% | 1.2−41.9%8.5% | 1.1−26.2%7.6% | 1.9−10.8%10.0% | 2.0+31.3%8.0% | 2.0+40.8%10.1% | 1.5—9.5% | 2.1—10.2% | 1.5—5.7% | 1.4—11.6% | |
| Current liabilities | 2.9—20.1% | 2.9−22.1%20.1% | 3.5+0.4%17.9% | 5.3+19.2%61.7% | 3.8+2.7%27.8% | 3.7−2.7%24.7% | 3.5−11.2%18.2% | 4.5+4.0%17.6% | 3.7−8.5%18.6% | 3.8—23.3% | 3.9—18.6% | 4.3—15.8% | 4.0—33.1% | |
| Total liabilities | 10—70.4% | 10−33.7%70.4% | 14+7.8%71.7% | 9.7−32.8%113% | 20+276%149% | 15+111%102% | 13+79.9%68.0% | 14+46.2%57.0% | 5.4+33.7%27.2% | 7.2—44.3% | 7.2—34.3% | 9.9—36.4% | 4.0—33.1% | |
| Retained earnings | −194—−1355% | −194—−1355% | −192—−984% | −184—−2141% | −189—−1393% | −179—−1197% | −171—−895% | −165—−650% | −160—−807% | −156—−959% | −150—−712% | −146—−538% | −146—−1199% | |
| Shareholders' equity | 4.2—29.6% | 4.2—29.6% | 5.5−9.7%28.3% | −1.1−110%−12.8% | −6.6−146%−48.9% | −0.3−103%−1.8% | 6.1−55.9%32.0% | 11−36.9%43.0% | 14+76.7%72.8% | 9.0—55.7% | 14—65.7% | 17—63.6% | 8.2—66.9% | |
| Total liabilities and equity | 14—100% | 14−4.2%100% | 20+2.2%100% | 8.6−66.0%100% | 14−31.3%100% | 15−8.0%100% | 19−9.4%100% | 25−6.6%100% | 20+62.4%100% | 16—100% | 21—100% | 27—100% | 12—100% | |
| Shares outstanding | 6.9—— | 6.9−51.6%— | 31+120%— | 16+12.7%— | 3.1r15−77.1%— | 14+32.5%— | 14+30.0%— | 14+30.1%— | 13+134%— | 11—— | 11—— | 11—— | 5.8—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | — | 0.0*—— | |
| Share-based compensation | 2.2−25.6%— | 0.5*−20.6%— | 0.5*−54.0%— | 0.6+2.2%— | 0.6*−1.6%— | 0.6*−20.0%— | 1.2*+142%— | 0.5+32.6%— | 0.6*—— | 0.8*—— | 0.5*—— | 0.4—— | — | |
| Cash from operating activities | −18—— | −3.9*—— | −4.6*—— | −4.9—— | −4.9*—— | −4.8*—— | −6.7*—— | −4.9—— | −5.0*—— | −4.7*—— | −6.8*—— | −4.7—— | −3.6*—— | |
| Capital expenditure | −0.0—— | 0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—— | −0.0*—— | −0.0*—— | 0*—— | 0—— | 0*—— | |
| Cash from investing activities | −0.5—— | −9.1*−360%— | 0.0*−68.7%— | 1.5—— | 7.1*—— | 3.5*−59.8%— | 0.1*−97.4%— | −1.2—— | −5.2*—— | 8.7*—— | 5.1*—— | −13—— | −2.7*—— | |
| Shares issued | 11+25.1%— | −0.8*—— | 12*—— | 0−100%— | 0*−100%— | 0*—— | 0*—— | 0.0−100.0%— | 8.9*—— | 0*—— | −0.1*—— | 19—— | 0*—— | |
| Cash from financing activities | 18−12.9%— | −1.0*−227%— | 15*—— | 0−100%— | 3.8*−57.9%— | 0.8*+5013%— | −0.1*—— | 11−43.6%— | 8.9*+4998%— | 0.0*—— | −0.0*—— | 19—— | 0.2*—— | |
| Change in cash | −0.9—— | −14*—— | 10*—— | −3.4−173%— | 6.1*—— | −0.4*−111%— | −6.6*—— | 4.6+277%— | −1.2*—— | 4.1*—— | −1.7*—— | 1.2—— | −6.1*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at CalciMedica, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025A. Rachel Leheny | $895 K | $2.4 M | $733 K | $230 |
| 2024A. Rachel Leheny | $1.7 M | $1.5 M | $1.3 M | $124 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at CalciMedica, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 1 · Auditor changed 1 · Directors and officers 5 · Material agreement 3 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2023 | $9 M | Private placement after listing | $2 to $10 million | 55 | equity, options | SEC |
| Jul 2019 | $55 M | No. 4 | $50 to $250 million | 8 | equity | SEC |
| Apr 2016 | $75 M | No. 3 | $50 to $250 million | 16 | equity | SEC |
| Feb 2015 | $2 M | No. 2 | Under $2 million | 2 | equity, options | SEC |
| Sep 2013 | $1 M | No. 1 | Under $2 million | 7 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How CalciMedica, Inc. compares in Biotechnology
- Market cap$12 M · higher than 12% of 726
- FCF yield-175.7% · higher than 2% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CalciMedica, Inc.🇺🇸 | $12 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CalciMedica, Inc.? Verify and update this profile — free
Show CalciMedica, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.